Upstream Bio (UPB) Competitors $8.78 +0.36 (+4.28%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$8.76 -0.01 (-0.17%) As of 04/17/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock UPB vs. IRON, TVTX, SDGR, IDYA, MESO, IMCR, INDV, CGON, VERA, and SPRYShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include Disc Medicine (IRON), Travere Therapeutics (TVTX), Schrödinger (SDGR), IDEAYA Biosciences (IDYA), Mesoblast (MESO), Immunocore (IMCR), Indivior (INDV), CG Oncology (CGON), Vera Therapeutics (VERA), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Upstream Bio vs. Disc Medicine Travere Therapeutics Schrödinger IDEAYA Biosciences Mesoblast Immunocore Indivior CG Oncology Vera Therapeutics ARS Pharmaceuticals Upstream Bio (NASDAQ:UPB) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk. Do analysts prefer UPB or IRON? Upstream Bio presently has a consensus price target of $56.50, indicating a potential upside of 543.51%. Disc Medicine has a consensus price target of $93.80, indicating a potential upside of 122.43%. Given Upstream Bio's higher probable upside, equities research analysts clearly believe Upstream Bio is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has preferable earnings and valuation, UPB or IRON? Upstream Bio has higher revenue and earnings than Disc Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpstream Bio$2.37M198.72N/AN/AN/ADisc MedicineN/AN/A-$76.43M-$3.99-10.57 Does the media favor UPB or IRON? In the previous week, Upstream Bio and Upstream Bio both had 4 articles in the media. Upstream Bio's average media sentiment score of 1.46 beat Disc Medicine's score of 0.76 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in UPB or IRON? 83.7% of Disc Medicine shares are held by institutional investors. 4.2% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is UPB or IRON more profitable? Upstream Bio's return on equity of 0.00% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Upstream BioN/A N/A N/A Disc Medicine N/A -25.24%-23.96% Does the MarketBeat Community prefer UPB or IRON? Disc Medicine received 54 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 86.57% of users gave Disc Medicine an outperform vote. CompanyUnderperformOutperformUpstream BioOutperform Votes4100.00% Underperform VotesNo VotesDisc MedicineOutperform Votes5886.57% Underperform Votes913.43% SummaryUpstream Bio and Disc Medicine tied by winning 6 of the 12 factors compared between the two stocks. Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$470.97M$6.45B$5.30B$7.35BDividend YieldN/A3.25%5.12%4.31%P/E RatioN/A6.8821.7117.77Price / Sales198.72231.36379.3997.68Price / CashN/A65.6738.2234.64Price / BookN/A5.916.443.98Net IncomeN/A$142.72M$3.21B$247.44M7 Day Performance37.19%7.98%5.24%4.44%1 Month Performance-11.04%-13.91%-9.49%-7.73%1 Year PerformanceN/A-9.98%11.01%1.28% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream BioN/A$8.78+4.3%$56.50+543.5%N/A$470.97M$2.37M0.0038Positive NewsIRONDisc Medicine2.6271 of 5 stars$39.20-4.9%$93.80+139.3%+39.3%$1.36BN/A-9.8530Gap UpHigh Trading VolumeTVTXTravere Therapeutics2.6074 of 5 stars$15.17+1.2%$31.46+107.4%+149.1%$1.35B$233.18M-3.70460SDGRSchrödinger2.5327 of 5 stars$18.21+1.0%$32.29+77.3%+2.8%$1.33B$207.54M-7.78790Analyst ForecastInsider TradeNews CoverageIDYAIDEAYA Biosciences3.5552 of 5 stars$15.14+2.9%$53.58+253.9%-57.5%$1.33B$7M-4.5980High Trading VolumeMESOMesoblast2.5768 of 5 stars$10.40-1.6%$18.00+73.1%+114.0%$1.32B$5.67M0.0080Positive NewsGap UpIMCRImmunocore2.3765 of 5 stars$26.28-3.6%$65.18+148.0%-47.9%$1.31B$310.20M-27.66320INDVIndivior3.7522 of 5 stars$9.39+2.6%$15.00+59.7%-53.2%$1.29B$1.19B-26.831,164Upcoming EarningsShort Interest ↓Positive NewsCGONCG Oncology1.2577 of 5 stars$16.92-1.6%$63.88+277.5%-43.3%$1.29B$1.14M-11.9261Analyst ForecastPositive NewsHigh Trading VolumeVERAVera Therapeutics2.975 of 5 stars$19.94-6.4%$64.67+224.3%-46.8%$1.27BN/A-7.6440Positive NewsHigh Trading VolumeSPRYARS Pharmaceuticals3.0888 of 5 stars$12.83+0.2%$31.00+141.6%+64.2%$1.26B$89.15M-25.1690Positive NewsHigh Trading Volume Related Companies and Tools Related Companies IRON Alternatives TVTX Alternatives SDGR Alternatives IDYA Alternatives MESO Alternatives IMCR Alternatives INDV Alternatives CGON Alternatives VERA Alternatives SPRY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPB) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UPB Stock Free UPB Stock Alerts